Pharmaceutical Technology: Controlled Drug Release, Volume 2

More documents

Recommendations

Info

MATRIX FORMULATIONS [CH. 4 45 (4) Grinding and separation of the particle size ranges in a Russell vibratory machine (Russell Finex, London and New York). (5) Lubrication for 3 min. (6) Final compression on the same instrumented tablet machine to obtain a 400 mg tablet. TESTS PERFORMED Powder test Powder flow rate was determined using a glass funnel. The volume before and after tapping (∆V=V 10 −V 500 ) was measured with an Eberhard Bauer (J.Engelsmann AG) tapping volume meter [14–16]. Physics of compression In sampling ten tablets, the following parameters were studied: the lubrication index (R), the ejection force (F c ), the residual force (F r ) and the cohesion index (CI=ratio of the pressure applied to the upper punch and the tensile strength) proposed by Guyot [17]. In one of the ten tablets, the mechanical work was calculated using the parameter of the total energy liberated during the compression (E t ). In sampling 120 tablets, the friability, the variability of the tablet weight and the variability of the upper punch force were determined. Tablet tests Friability was determined with 20 tablet samples in a friability tester (Erweka TA3R; 15 min, 25 rev min −1 ). The weight variation was evaluated for 20 tablets on an electronic balance (Mettler AK 260; Sofranie). Tablet hardness was measured on 10 tablets using a Schleuniger hardness tester (Soteco). Dissolution studies Six tablets were subjected to. dissolution using the USP dissolution apparatus (Vanderkamp 600, Van-Kel Ind., NJ, USA) in 500 ml buffer pH 1.2 (the first hour) and 650 ml buffer pH 6.8 (1–14 h), maintained at 37°C and rotated with paddles at 50 rev min −1 (first hour) and 130 rev min −1 (1–14 h). The dissolution apparatus was connected to a UV-visible spectrophotometer (Uvikon 810, Roxche Bioéléctronique Kontron, Marseille) and a computer (VAX 780; Digital). The absorbance of the dissolution medium at 275 nm was recorded automatically at intervals (1, 2, 4, 5, 8, 10, 12 and 14 h). The percentage of the drug released was calculated and the corresponding release profiles were obtained.
46 CH. 4] STATISTICAL OPTIMIZATION OF A CONTROLLED RELEASE FORMULATION PRELIMINARY TRIALS The objective of the preliminary trials was to define the best way to incoporate the lubricants, i.e. before or after the precompression operation. Three experiments were carried out. (1) Experiment A. Talc was added before precompression and magnesium stearate before the final compression. (2) Experiment B. 50% of each lubricant was incorporated before and after precompression. (3) Experiment C. Magnesium stearate was mixed before precompression and talc before the final compression. In these three experiments, 50% of the ethylcellulose was added before precompression and the other 50% before the final compression. Precompression was conducted at 10 kN (UPF) and a 10 mm depth of the die. After milling and grinding, the 100–800 µm particle size range was collected and lubricated. For final compression, the powder was compresseed at 10 kN. Results and discussion Results obtained from the preliminary trials described above are shown in Table 1. The mean values of three trials performed for validation of the optimized formulation by direct compression [13] are given for comparison. The release profiles are illustrated in Fig. 1. As expected, the flow rate, ∆V, R, F e , F r , E t , UPF variation and weight variation were better than for direct compression. CI and friability were affected owing to the poor crushing strength (hardness) of the tablets obtained af ter the final compression. Double compression largely decreases the coefficients of variation of the percentage dissolved at 8 h and AUC. Adding lubricants before or after precompression reveals an effect on the different studied properties. Experiments A and B give better values than experiment C. In addition, the parameters R, F e , F r and CI are affected when talc is added alone before the final compression. In conclusion, the incorporation of 50% magnesium stearate and talc before precompression and the other 50% before the final compression improves the compression behaviour. At the same time, it decreases the coefficients of variation of UPF the weight of the tablet and dissolution parameters. From these results, the process from experiment B was chosen for the experimental designs. APPLICATION OF A HADAMARD MATRIX H(8) Experimental design The theory and application of a Hadamard matrix were discussed by Ozil and Rochat [18]. This design is an optimum strategy leading to good accuracy in the main effects
Page 2 and 3: PHARMACEUTICAL TECHNOLOGY Controlle
Page 4 and 5: 3 TABLET MACHINE INSTRUMENTATION IN
Page 6 and 7: First published in 1991 by ELLIS HO
Page 8 and 9: 7 10 Controlled delivery of theophy
Page 10: Slow and steady wins the race Poems
Page 14 and 15: 1 Influence of drug solubility in t
Page 16 and 17: CH. 1] INFLUENCE OF DRUG SOLUBILITY
Page 22: CH. 1] INFLUENCE OF DRUG SOLUBILITY
Page 25 and 26: 24 MATRIX FORMULATIONS [CH. 2 MATER
Page 27 and 28: 26 MATRIX FORMULATIONS [CH. 2 Fig.
Page 29 and 30: 28 MATRIX FORMULATIONS [CH. 2 Table
Page 31 and 32: 30 MATRIX FORMULATIONS [CH. 2 The e
Page 35 and 36: 34 CH. 3] THE FORMULATION OF SUSTAI
Page 44 and 45: 4 Statistical optimization of a con
Page 48 and 49: MATRIX FORMULATIONS [CH. 4 47 Fig.
Page 50 and 51: Columns 1-4 lead to the matrix of e
Page 52 and 53: MATRIX FORMULATIONS [CH. 4 51 Table
Page 54 and 55: MATRIX FORMULATIONS [CH. 4 53 Fig.
Page 56: Fig. 5—Linearization of the relea
Page 59 and 60: 58 MATRIX FORMULATIONS [CH. 5 Pevik
Page 61 and 62: 60 MATRIX FORMULATIONS [CH. 5 The d
Page 72 and 73: 6 Controlled release matrix tablets
Page 74 and 75: CH. 6] CONTROLLED RELEASE MATRIX TA
Page 80 and 81: 7 A new ibuprofen pulsed release or
Page 82 and 83: CH. 7] A NEW IBUPROFEN PULSED RELEA
Page 88: CH. 7] A NEW IBUPROFEN PULSED RELEA
Page 91 and 92: 90 CH. 8] TOPICAL RELEASE AND PERME
Page 97 and 98:
96 CH. 8] TOPICAL RELEASE AND PERME
Page 99 and 100:
98 CH. 8] TOPICAL RELEASE AND PERME
Page 101 and 102:
100
Page 103 and 104:
102
Page 105 and 106:
104 MULTIPARTICULATES [CH. 9 parace
Page 107 and 108:
106 MULTIPARTICULATES [CH. 9 (a) th
Page 109 and 110:
108 MULTIPARTICULATES [CH. 9 Fig. 2
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
116
Page 119 and 120:
118 CH. 10] CONTROLLED DELIVERY OF
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
126 CH. 11] THE EFFECT OF FOOD ON G
Page 129 and 130:
128 CH. 11] THE EFFECT OF FOOD ON G
Page 131 and 132:
130
Page 133 and 134:
132 CH. 12] BIODEGRADABLE POLYMERS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
140
Page 143 and 144:
142 CH. 13] A COMPARISON OF DISSOLU
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
152
Page 155 and 156:
154
Page 157 and 158:
156 OPHTHALMIC FORMULATION [CH. 14
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
162 CH. 15] A SUSTAINED RELEASE OPH
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
170
Page 173 and 174:
172 IMPLANTS [CH. 16 The purpose of
Page 175 and 176:
174 IMPLANTS [CH. 16 times with 5 m
Page 177 and 178:
176 IMPLANTS [CH. 16 noted that the
Page 179 and 180:
178 IMPLANTS [CH. 16 Fig. 1—The e
Page 181 and 182:
180 IMPLANTS [CH. 16 Table 3—Tobr
Page 183 and 184:
182
Page 185 and 186:
184 CH. 17] SILICON MATRIX SYSTEMS
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
192
Page 195 and 196:
194 INDEX dry granulation, 43 elect
show all

Pharmaceutical Technology: Controlled Drug Release, Volume 2

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?